Chronic pain is a major public health concern that has immense societal and economic impacts. Worldwide, more than 1.5 billion people suffer from some type of chronic pain. In the US alone, pain affects more than 50 million adults and costs society an estimated $560 to $635 billion, outranking heart disease, cancer, and diabetes combined.
In recent years, the number of overdose deaths in the US involving opioids has skyrocketed, and the overuse of prescription opioids as a primary pain management tool is part of the problem. Could focused ultrasound offer a way to stem this addiction crisis?
In 2014, FUSMobile co-founders Arik Hananel, MD, and Ron Aginsky, LLB, MBA, identified a need for a compact, mobile, and user-friendly focused ultrasound device. Less than five years later, their company has completed a pilot clinical trial using their Neurolyser device.
Tammy's hip pain started in 2010. When medications, surgeries, and nerve stimulator implants didn't help, she researched other options and found a focused ultrasound trial at the University of Maryland.